Organogenesis (NASDAQ:ORGO – Get Free Report) and Incyte (NASDAQ:INCY – Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, valuation, analyst recommendations and dividends.
Insider and Institutional Ownership
49.6% of Organogenesis shares are held by institutional investors. Comparatively, 97.0% of Incyte shares are held by institutional investors. 18.8% of Organogenesis shares are held by insiders. Comparatively, 16.2% of Incyte shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Risk and Volatility
Organogenesis has a beta of 1.48, meaning that its stock price is 48% more volatile than the S&P 500. Comparatively, Incyte has a beta of 0.78, meaning that its stock price is 22% less volatile than the S&P 500.
Profitability
This table compares Organogenesis and Incyte’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Organogenesis | -39.34% | -55.28% | -23.72% |
| Incyte | 6.71% | 7.92% | 6.12% |
Analyst Recommendations
This is a breakdown of recent ratings for Organogenesis and Incyte, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Organogenesis | 1 | 2 | 0 | 0 | 1.67 |
| Incyte | 0 | 14 | 11 | 0 | 2.44 |
Organogenesis currently has a consensus price target of $4.33, indicating a potential upside of 434.91%. Incyte has a consensus price target of $132.86, indicating a potential upside of 9.83%. Given Organogenesis’ higher possible upside, analysts plainly believe Organogenesis is more favorable than Incyte.
Earnings & Valuation
This table compares Organogenesis and Incyte”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Organogenesis | $564.17 million | 0.19 | $37.03 million | ($1.22) | -0.66 |
| Incyte | $6.01 billion | 4.10 | $1.29 billion | $1.88 | 64.35 |
Incyte has higher revenue and earnings than Organogenesis. Organogenesis is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks.
Summary
Incyte beats Organogenesis on 11 of the 14 factors compared between the two stocks.
About Organogenesis
Organogenesis Holdings Inc. is a regenerative medicine company that develops, manufactures and commercializes products for advanced wound care and surgical and sports medicine. The company’s products are designed to support tissue repair and healing in a range of clinical settings. Its portfolio includes wound-care products such as Apligraf, a bioengineered skin substitute, and products made from or incorporating materials including placental tissue and purified collagen. Organogenesis also offers products for surgical and sports medicine applications.
About Incyte
Incyte is a biopharmaceutical company that discovers, develops and commercializes medicines, with a focus on oncology, hematology and inflammatory and autoimmune diseases. Founded in 1991, the company is headquartered in Wilmington, Delaware, and conducts research and commercial activities in the United States and internationally. Its products include Jakafi (ruxolitinib), used to treat certain blood disorders and graft-versus-host disease, and Opzelura (ruxolitinib cream), approved in the United States for certain skin conditions.
Receive News & Ratings for Organogenesis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organogenesis and related companies with MarketBeat.com's FREE daily email newsletter.
